1-3 of 3
Leilani Ruf, MD
Close
Sort by
Journal Articles

Molecular Level of Minimal Residual Disease in Bone Marrow Before High-Dose Therapy and Autologous Stem Cell Transplantation Is a Prognostic Parameter in Patients with Multiple Myeloma.

Roland Fenk, MD, Mark Korthals, Nina Sehnke, Ingmar Bruns, MD, Akos Czibere, MD, Fabian Zohren, Nancy Safaian, Ariane Dienst, Leilani Ruf, MD, Frank Neumann, MD, Rainer Haas, MD, Ralf Kronenwett, MD, Guido Kobbe, MD
Journal: Blood
Blood (2007) 110 (11): 1496.
https://doi.org/10.1182/blood.V110.11.1496.1496
Published: 2007
Journal Articles

Comparison of Interferon Versus Thalidomide Versus RIC Allotransplant for Maintenance /Consolidation Therapy after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: A Single Center Experience.

Roland Fenk, MD, Thorsten Graef, MD, Ingmar Bruns, MD, Leilani Ruf, MD, Zohren Fabian, MD, Ulrich Steidl, MD, Ali-Nuri Huenerlituerkoglu, MD, Rainer Haas, Guido Kobbe, MD
Journal: Blood
Blood (2005) 106 (11): 1168.
https://doi.org/10.1182/blood.V106.11.1168.1168
Published: 2005
Journal Articles

Pre-Transplantation Level of Minimal Residual Disease Detected by Quantitative Real-Time IgH-PCR Is a Prognostic Parameter in Patients with Multiple Myeloma.

Roland Fenk, MD, Mark Korthals, Guido Kobbe, MD, Ulrich Steidl, MD, Thorsten Graef, MD, Ulrich-Peter Rohr, MD, Leilani Ruf, MD, Barbara Hoyer, MD, Frank Neumann, MD, Rainer Haas, MD, Ralf Kronenwett, MD
Journal: Blood
Blood (2004) 104 (11): 4871.
https://doi.org/10.1182/blood.V104.11.4871.4871
Published: 2004